Journal of Clinical Medicine · مجلد 15 (6) · 2114-2114
Background: C-reactive protein (CRP), a biomarker of systemic inflammation, has been implicated in adverse pregnancy and neonatal outcomes. However, the relationship between maternal CRP and neonatal complications remains unclear. We conducted a systematic review and meta-analysis to synthesize available evidence. Methods: We systematically searched PubMed, Scopus, Web of Science, and Cochrane Library up to July 2025 for observational studies reporting maternal CRP levels in relation to neonatal outcomes. Eligible outcomes included preterm birth (PTB), low birth weight (LBW), small for gestational age (SGA), and stillbirth. Random-effects models were used to calculate pooled standardized mean differences (SMD) or odds ratios (OR) with 95% confidence intervals (CI). Statistical heterogeneity was assessed using the I2 statistic. Results: The search yielded 6843 records, of which 42 studies (comprising 18,393 pregnant women) met the inclusion criteria. Maternal mean CRP levels were significantly higher in adverse pregnancy outcomes compared with controls (SMD = 0.39; 95% CI 0.08–0.70; p = 0.01; I2 = 96.6%). Elevated CRP was strongly associated with PTB (OR = 3.81; 95% CI 2.66–5.47; p < 0.001; I2 = 85%; n = 23) and LBW (OR = 2.34; 95% CI 1.35–4.03; p = 0.002; I2 = 84.2%; n = 7). No significant associations were observed for SGA (OR = 1.14; 95% CI 0.86–1.49; p = 0.36; I2 = 0%; n = 5) or stillbirth (OR = 1.89; 95% CI 0.92–3.90; p = 0.08; I2 = 44.9%; n = 4). Conclusion: Maternal CRP is significantly associated with increased risks of preterm birth and low birth weight but not with SGA or stillbirth. These findings support the role of systemic inflammation in adverse neonatal outcomes and highlight the need for prospective studies to clarify causal mechanisms and assess the clinical utility of CRP in pregnancy risk stratification.
Annals of Middle Eastern Medicine · مجلد 2 (3) · 302-311
This systematic review and meta-analysis evaluated preoperative patient factors associated with adverse outcomes after primary total knee arthroplasty (TKA). PubMed and Crossref were searched from 2010 to 2025 according to PRISMA guidance, and the protocol was registered in PROSPERO (CRD420261297849). Eligible studies included adults undergoing primary TKA and reported diabetes mellitus, hypertension, obesity, morbid obesity, or sex in relation to readmission, revision surgery, or deep infection. Random-effects generic inverse variance meta-analyses were performed using odds ratios from adjusted models when available; unadjusted or calculated estimates were used only when adjusted estimates were unavailable. Twelve cohort studies including 1,586,680 patients were included. Diabetes mellitus was associated with higher odds of readmission (OR 1.17, 95% CI 1.05-1.30) and revision surgery (OR 1.17, 95% CI 1.03-1.32). Morbid obesity (BMI ≥40 kg/m²) was associated with readmission, revision surgery, and deep infection. Male sex was associated with readmission and revision surgery, while non-morbid obesity and hypertension were not consistently associated with adverse outcomes. These findings support preoperative risk stratification and optimization for diabetes and morbid obesity before elective TKA. Interpretation should remain cautious because included studies were observational and heterogeneity was substantial in several analyses.
total knee arthroplastypreoperative risk factorsadverse outcomesdiabetes mellitus
Journal of Pioneering Medical Science · مجلد 14 (Special Issue 1) · 464-472
Background: Androgenetic alopecia (AGA) is the most common disorder of hair loss in men and women. Minoxidil is one of the drugs that are widely used for the treatment of hair loss and commercially available as oral or topical preparations. This systematic review with meta-analysis was thus intended to compare the efficacy and safety profile of oral minoxidil and topical minoxidil in the treatment of AGA. Methods: A systematic literature search was conducted across seven major databases: PubMed, Scopus, Web of Science, Cochrane Library, Embase, CINAHL and PsycINFO. After close filtering, four studies were selected for meta-analysis where the efficacy and safety of oral and topical minoxidil for the treatment of AGA were studied. Results: Meta-analytic results did not express a statistically significant superiority of oral minoxidil over the topical minoxidil in promoting healthy hair growth, that is, the odds ratio 2.23 (95% CI: 0.84, 5.93) with a p-value 0.11 for a test of overall effect and Z = 1.60, with heterogeneity (Tau²=0.00); meaning homogeneity among the studies. The incidence of adverse events was also more in the oral minoxidil compared to the oral finasteride. However, it included hypertrichosis, tachycardia and scalp pruritus with OR, 3.33 (95% CI: 1.40, 7.90) and p-value of 0.006. Qualitatively, the studies unveiled that oral and topical minoxidil have efficacy in the treatment of AGA but to different degrees of efficacy and tolerability. Conclusion: The clinical benefits of oral and topical minoxidil were the same when used in the treatment of AGA, however, hair density improved better with topical minoxidil and adverse effects were minimum.
Frontiers in Pharmacology · مجلد 15 · 1434512-1434512
Background: Parkinson’s disease (PD) is a neurological condition that typically shows up with aging. It is characterized by generalized slowness of movement, resting tremor or stiffness, and bradykinesia. PD patients’ brains mostly exhibit an increase in inflammatory mediators and microglial response. Nevertheless, a variety of non-steroidal anti-inflammatory medications (NSAIDS) offered neuroprotection in animal models and preclinical trials. Aim: The current systematic review and meta-analysis were designed to try to resolve the debate over the association of NSAID use with the development of PD because the results of several studies were somehow contradictory. Methods: An intense search was performed on Scopus, PubMed, and Web of Science databases for articles relating the incidence of PD to the use of NSAIDs. Statistical analysis of the included studies was carried out using Review Manager version 5.4.1 by random effect model. The outcome was identified as the development of PD in patients who were on NSAIDs, ibuprofen only, aspirin only, and non-aspirin NSAIDs. This was analyzed using pooled analysis of odds ratio (OR) at a significance level of ≤0.05 and a confidence level of 95%. A statistically significant decreased risk of PD was observed in patients taking NSAIDs, Ibuprofen, and non-aspirin NSAIDs. Results: The ORs of PD occurrence in patients who took NSAIDs, Ibuprofen, and non-aspirin NSAIDs were 0.88 [95% CI (0.8–0.97), p = 0.01], 0.73 [95% CI (0.53–1), p = 0.05] and 0.85 [95% CI (0.75–0.97), p = 0.01]. Meanwhile, the risk of PD in patients who took aspirin was not statistically significant. Conclusion: In conclusion, Ibuprofen, non-aspirin NSAIDs, and other types of NSAIDs could be associated with a reduction in PD risk. However, there was no association between aspirin intake and the development of PD.
Journal of Infection and Public Health · مجلد 17 (4) · 579-587
Dengue hemorrhagic fever (DHF) is a severe condition resulting from the dengue virus, with four serotypes known as DEN-1, DEN-2, DEN-3, and DEN-4. Genetic variations play a crucial role in influencing susceptibility to DHF. Therefore, this investigation conducted a meta-analysis to uncover genetic changes that might have remained undetected in individual studies due to small sample sizes or methodological differences. Among 2212 initially identified studies, 23 were deemed suitable for analysis based on PRISMA guidelines. Toll-like receptors (TLR) and CD209 showed significant association with DHF (odds ratios: TLR=0.56, CD209 =0.55), indicating protective effects. However, tumor necrosis factor (TNF) and human leukocyte antigen (HLA) did not exhibit a statistically significant relationship with DHF. This study emphasizes the relevance of TLR and CD209 in DHF susceptibility and resistance across diverse geographical locations.
BACKGROUND: This study aimed to summarize the current literature regarding the prevalence of renal stones in patients with inflammatory bowel disease (IBD). Moreover, we aimed to evaluate the risk factors of urolithiasis in patients with IBD and the difference between patients with IBD and healthy controls in terms of urinary profile. METHODS: On February 23, 2022, a computerized search was conducted on PubMed, OVID via MEDLINE, Web of Science, and Scopus using relevant keywords. Three independent reviewers performed 2-stage screening and data extraction. The National Institutes of Health tools were employed for quality assessment. Review Manager 5.4 software was used to calculate the mean difference (MD) between IBD patients and non-IBD in terms of urine profile using the Inverse-variance model and to estimate the odds ratio of reported risk factors for renal stones with the Generic Inverse-Variance model. RESULTS: Thirty-two articles (n = 13,339,065 patients) were included. The overall prevalence of renal stones in patients with IBD was 6.3%, 95% Confidence interval (4.8%-8.3%). The prevalence of urolithiasis was more common in Chron's disease vs Ulcerative colitis (7.9% vs 5.6%) and in old studies (1964-2009) than in more recent studies (2010-2022) (7.3% vs 5.2%), respectively. Compared to non-IBD patients, patients with IBD were associated with significantly lower urine volume (MD = -518.84 mL/day, P < .00001), calcium 24-hour urine (MD = -28.46 mg/day, P < .0001), citrate 24-hour urine (MD = -144.35 mg/day, P < .00001), sodium 24-hour urine (MD = -23.72 mg/day, P = .04), and magnesium 24-hour urine (MD = -33.25 mg/day, P < .00001). CONCLUSION: The overall prevalence of renal stones in patients with IBD was comparable to the general population. Patients with Chron's disease were associated with a higher prevalence of urolithiasis compared to Ulcerative colitis. Drugs that induce renal calculi should be stopped in high-risk patients.
Background: We aimed to summarize and synthesize the current evidence regarding the indirect impact of the coronavirus disease 2019 (COVID-19) pandemic and its associated measures on the surgical site infection (SSI) rate compared with the pre-pandemic period. Methods: A computerized search was conducted on MEDLINE via PubMed, Web of Science, and Scopus using the relevant keywords. Two-stage screening and data extraction were done. The National Institutes of Health (NIH) tools were used for the quality assessment. The Review Manager 5.4.1 program was used for the analysis. Results: Sixteen articles (n = 157,426 patients) were included. The COVID-19 pandemic and lockdown were associated with reduced risk of SSIs after surgery (odds ratio [OR], 0.65; 95% confidence interval [CI], 0.56–0.75; p < 0.00001) and (OR, 0.49; 95% CI, 0.29–0.84; p = 0.009), respectively. There was no significant reduction in the SSIs rate after applying the extended use of masks (OR, 0.73; 95% CI, 0.30–1.73; p = 0.47). A reduction in the superficial SSI rate during the COVID-19 pandemic compared with the pre-COVID-19 pandemic period was observed (OR, 0.58; 95% CI, 0.45–0.75; p < 0.0001). Conclusions: The current evidence suggests that the COVID-19 pandemic may have some unexpected benefits, including improved infection control protocols, which resulted in reduced SSI rates, especially superficial SSIs. In contrast to extended mask use, the lockdown was associated with reduced rates of SSIs.
COVID-19 pandemicsurgical site infectionlockdownmasking